Resource Summary Report

Generated by NIF on Aug 30, 2026

p44/42 MAP kinase (phosphorylated Erk1/2)

RRID:AB_331646
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9101, RRID:AB_331646

Antibody Information

URL: http://antibodyregistry.org/AB_331646

Proper Citation: Cell Signaling Technology Cat# 9101, RRID:AB_331646

Target Antigen: Erk1/2

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IF-IC, F
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE
Consolidation: AB_2315036, AB_2315114, AB_2315111, AB_2315113, AB_331647

Antibody Name: p44/42 MAP kinase (phosphorylated Erk1/2)

Description: This polyclonal targets Erk1/2

Target Organism: Human, D.melanogaster, Bovine, Rat, Monkey, Zebrafish, C.elegans, Pig, Mouse, Mink, Hamster

Defining Citation: PMID:19937707, PMID:18196540, PMID:18459137

Antibody ID: AB_331646

Vendor: Cell Signaling Technology

Catalog Number: 9101

Alternative Catalog Numbers: 9101S, 9101L

Record Creation Time: 20250820T023650+0000

Record Last Update: 20250820T140318+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for p44/42 MAP kinase (phosphorylated Erk1/2).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 802 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Shaheen MT, et al. (2026) The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. Cancer research communications, 6(1), 245.

Luo Z, et al. (2026) LDHB Deficiency in Fibroblasts Induces Lactate-Mediated Inflammatory Reprogramming That Promotes Breast Cancer Metastasis. Cancer research, 86(11), 2703.

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. Cell reports, 45(3), 117046.

Auletta F, et al. (2026) CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. Cell death discovery, 12(1).

Chan S, et al. (2026) The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis. British journal of pharmacology, 183(15), 4126.

Mahmoud A, et al. (2026) An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis. Developmental cell, 61(6), 1289.

Martín A, et al. (2026) Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.

Cancer research.

Luo YE, et al. (2026) Resident mesenchymal progenitor cells require autocrine IGF-I in homeostatic and regenerating skeletal muscle. Stem cell reports, 21(7), 102973.

Shen Q, et al. (2026) FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance. Cell metabolism.

Zhang M, et al. (2026) Microglia prune developing cortical blood vessels through PD-1 signaling. Nature neuroscience.

Yao L, et al. (2026) Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine, 102928.

Yeh H, et al. (2026) Chemical characterization of Jing Guan Fang and its application in alleviating coronavirus envelope protein-induced proinflammatory responses in vitro and in vivo. Journal of traditional and complementary medicine, 16(3), 331.

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. Cell death & disease, 17(1), 187.

Sorrenti E, et al. (2026) Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer. Cell host & microbe, 34(3), 425.

Chattopadhyay A, et al. (2026) Microsomal triglyceride transfer protein restricts steroid production in Leydig cells by regulating SREBP2. iScience, 29(6), 115817.

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion. Immunity.

Fidaleo AM, et al. (2026) LRRC8A-containing anion channels promote glioblastoma proliferation via a WNK1/mTORC2-dependent mechanism. The Journal of physiology, 604(5), 1995.

Blackburn E, et al. (2026) Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons. Cell death & disease, 17(1), 214.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. Cancer research, 86(5), 1252.

Kremmyda P, et al. (2026) SHP2 regulates VEGFR2 Y1175/PLC? signaling to impair tumor endothelial barrier stability. iScience, 29(2), 114784.